share_log

Goldman Sachs Initiates Coverage On Revance Therapeutics With Buy Rating, Announces Price Target of $33

Goldman Sachs Initiates Coverage On Revance Therapeutics With Buy Rating, Announces Price Target of $33

高盛以买入评级启动对Revance Therapeutics的报道,宣布目标股价为33美元
Benzinga Real-time News ·  2022/09/22 06:21

Goldman Sachs analyst Chris Shibutani initiates coverage on Revance Therapeutics (NASDAQ:RVNC) with a Buy rating and announces Price Target of $33.

高盛分析师克里斯·希布塔尼开始对Revance Therapeutics(纳斯达克股票代码:RVNC)进行报道,评级为买入,并宣布目标股价为33美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发